| Akouos is a genetic medicine company, engaged in developing gene therapies to restore, improve, and preserve physiologic hearing for individuals who live with disabling hearing loss. Co. has a genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus used in gene therapy, known as adeno-associated virus, and a delivery approach. Co. is developing its product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of etiology, such as AK-antiVEGF for vestibular schwannoma. We show 10 historical shares outstanding datapoints in our AKUS shares outstanding history coverage, used to compute AKUS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AKUS market cap history over the course of time is important for investors
interested in comparing AKUS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AKUS versus a peer is one thing; comparing
AKUS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AKUS can fluctuate over the course of history.
With this page we aim to empower investors researching AKUS by allowing them to research the AKUS market cap history.